NT_1170x120_1-11-18

David Ricks

Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

INDIANAPOLIS — Reinforcing their commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Co. announced it will introduce a lower-priced version of Humalog (insulin lispro injection 100 units/mL) in the United States — providing people with diabetes an insulin option that will have a list price 50 percent lower than the current

Eli Lilly earmarks funds for insulin facility upgrade

Eli Lilly earmarks funds for insulin facility upgrade

INDIANAPOLIS — Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. Eli Lilly said the investment will be used to replace a current insulin vial-filling line. The move also stands to enable the company to meet rising demand for its insulins — including Humalog

Eli Lilly to acquire CoLucid for $960 million

Eli Lilly to acquire CoLucid for $960 million

INDIANAPOLIS — Eli Lilly and Co. plans to buy CoLucid Pharmaceuticals Inc., maker of a promising migraine medication, for about $960 million in cash. Cambridge, Mass.-based CoLucid is currently in development with lasmiditan tablets, indicated for acute treatment of migraine, and has completed the first of two Phase 3 trials. A data read-out for the